ASAHI KASEI (3407) FY2027 Q1 Earnings Report

Quick View

Executive Summary

For Q1 of the fiscal year ending March 2027, revenue and profit increased, primarily due to a significant earnings improvement in the core Materials segment, resulting in a clear recovery in profitability. Revenue was ¥8,261.6B (+11.9% YoY), Operating Income was ¥813.0B (+51.5%), Ordinary Income was ¥853.3B (+70.8%), and Net Income attributable to owners of the parent was ¥537.7B (+172.7%). The Operating Income margin improved by approximately 2.5pt from the same period of the previous year to 9.8%, achieving profit growth that exceeded revenue growth. In addition to the absence of the loss related to the withdrawal from businesses such as MMA, which was recorded in the same period of the previous year, positive inventory valuation effects during a period of rising raw material and fuel prices associated with the situation in the Middle East also boosted earnings.

Factors Affecting Results

【Revenue】Revenue increased 11.9% YoY to ¥8,261.6B. Materials grew substantially by +13.8%, Healthcare by +23.0%, and Housing also increased revenue by +3.3%; however, Housing’s overseas business was pressured by declining demand in North America.

【Profit and Loss】Operating Income was ¥813.0B (+51.5% YoY), with Materials’ Operating Income surging 160.4% and driving company-wide profit growth. Ordinary Income was ¥853.3B (+70.8%), boosted by a foreign exchange gain of ¥49.6B. Special gains and losses amounted to a net gain of only ¥11.3B; although temporary factors such as a gain on the sale of investment securities of ¥23.2B were present, they were not the primary driver of profit expansion. The reversal of business structure improvement expenses, including impairment losses, recorded in the same period of the previous year also contributed to the substantial increase in Net Income. In conclusion, the results represent revenue and profit growth driven by the recovery in profitability of the core Materials Business.

Segment Analysis

By segment, Materials recorded the largest increase in Operating Income at ¥388.1B (+160.4% YoY; margin 10.7%), accounting for slightly more than 40% of reported segment profit and driving company-wide earnings growth as the core business. Although Healthcare ranks second to Materials in terms of revenue mix, it has the highest profitability, with a margin of 15.6%, and continued stable growth, recording Operating Income of ¥297.6B (+31.4%). Housing increased revenue to ¥2,705.6B (+3.4%), but Operating Income declined to ¥201.8B (-9.7%), as declining demand in North America and material costs pressured profitability. Among the segments, Housing’s 7.5% margin was below those of Healthcare and Materials, indicating a widening disparity in profitability by business.

Key Financial Metrics

Profitability: ROE 2.6% (improving compared with the same period of the previous year, reflecting the sharp increase in Net Income), Operating Income margin 9.8%
Cash quality: Operating CF/Net Income 0.27x (below 1.0x, indicating weak cash backing for earnings), Free CF -1,812.8B
Investment efficiency: Capital expenditures/Depreciation and amortization 1.29x (above 1.0x, indicating a period of growth investment)
Financial soundness: Equity Ratio 49.3%, Current Ratio 200.8%

Cash Flow Analysis

Operating CF was ¥142.5B, or 0.27x Net Income attributable to owners of the parent of ¥537.7B, indicating that cash generation has not kept pace with earnings growth. The main factor was a ¥732.5B increase in inventories, as inventory accumulation during a period of rising raw material and fuel prices pressured working capital. Investing CF was an outflow of ¥1,955.3B, primarily due to ¥1,316.8B for the acquisition of shares in subsidiaries, including the acquisition of Aicuris, and ¥556.9B in capital expenditures. Financing CF was an inflow of ¥1,859.7B, with net increases in short-term borrowings and bond issuance supplementing investment funding. Free CF was negative ¥1,812.8B, indicating a capital allocation structure in which major M&A and investments were financed with external funds. Cash generation is assessed as requiring monitoring.

Earnings Quality

The difference between Ordinary Income of ¥853.3B and Net Income attributable to owners of the parent of ¥537.7B was primarily attributable to income taxes of ¥303.2B. Net special gains and losses amounted to a gain of only ¥11.3B, indicating that special factors made a limited contribution to the difference between the two figures. Non-operating income of ¥135.4B was minor at 1.6% of revenue, although it included a foreign exchange gain of ¥49.6B. From an accrual perspective, Operating CF was substantially below Net Income, and the possibility that inventory valuation gains associated with increased inventories contributed to accounting earnings improvement warrants attention as an aspect of earnings quality.

Earnings Forecast and Guidance

Against the full-year company forecasts of revenue of ¥32,540B, Operating Income of ¥2,480B, and Ordinary Income of ¥2,475B, Q1 progress rates were 25.4% for revenue, 32.8% for Operating Income, and 34.5% for Ordinary Income, exceeding the standard 25% progress level by 7–10pt on a profit basis. A revision to the earnings forecast for the current quarter is indicated as having been made, with first-half forecasts of Operating Income of ¥1,450B (+34.9% YoY) and interim Net Income of ¥890B (+34.3%). The upside in progress is largely attributable to the sharp recovery in Materials and inventory valuation gains; the fact that these gains are expected to decrease toward Q2 will be a key focus going forward.

Shareholder Returns

The full-year dividend forecast is ¥44.0, implying a Payout Ratio of approximately 36.8% based on forecast EPS of ¥119.65. The interim dividend is forecast at ¥22, an increase of ¥2 from the previous year. During the current quarter, the company conducted share repurchases of ¥178.7B; combined with dividends, representing cash outflows of ¥299.1B, total shareholder returns amounted to ¥477.8B. When only dividends are included in the numerator, the measure is distinguished as the “Payout Ratio”; when share repurchases are included, it is distinguished as the “Total Return Ratio.” Free CF was negative during the current quarter, and the funding source for shareholder returns was primarily supplemented by financing activities.

Catalysts

【Short Term】Inventory valuation gains are expected to decline toward Q2, making the sustainability of Materials’ high profitability a key focus. Raw material and fuel prices and demand trends associated with the situation in the Middle East, as well as trends in North American demand and material costs in the Housing Business, will also require close monitoring.

【Long Term】Progress in commercializing businesses following M&A in the Healthcare field, including the Aicuris acquisition of ¥1,443B; capacity expansion investments in the Electronics field, such as Paimel; and progress in the structural transformation of the Materials Business, including the reconstruction of the Mizushima Plant, will affect the medium-term earnings structure.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

The Operating Income margin exceeds the industry median, while the Net Income margin is slightly below it, indicating that the advantage in operating-level profitability is partially offset at the Net Income level.

Growth and Capital Efficiency

The revenue growth rate is substantially above the industry median, placing the company in the upper group.

※Source: Compiled by the Company

Risk Factors

1. Inventory and Working Capital Risk: Inventories increased by ¥732.5B from the end of the previous fiscal year, reducing Operating CF to 0.27x Net Income. When inventory valuation gains decline, there is a risk of a reversal in profitability.

2. Profitability Disparities by Business: Although the Housing Business increased revenue, Operating Income declined 9.7%, affected by declining demand in North America and rising material costs. Compared with the sharp recovery in Materials, vulnerabilities remain in part of the earnings structure.

3. M&A Integration Risk: The Aicuris acquisition, which resulted in goodwill of ¥445.7B being recorded, with purchase price allocation still provisional, has increased interest-bearing debt and financial leverage. Progress in commercializing the acquired business will affect future earnings and cash flow.

Key Takeaways from the Earnings Results

1. The Operating Income margin improved by approximately 2.5pt from the same period of the previous year to 9.8%; however, the primary drivers of the improvement were the sharp recovery in the Materials segment and inventory valuation gains. Whether a reversal occurs from Q2 onward will be an important factor in assessing the sustainability of the earnings trend.

2. The fact that Operating CF is substantially below Net Income indicates weak cash backing for earnings during a period of profit growth. Monitoring the trend in inventory levels in conjunction with this metric would be useful.

3. Interest-bearing debt has increased due to aggressive M&A and investment activities, including the Aicuris acquisition. Although financial soundness, as measured by an Equity Ratio of 49.3%, has been maintained, progress in recovering investments will be an important factor in evaluating the future financial structure.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,606–¥1,701 at ±1% in the cost of equity, and ¥1,651–¥1,656 at ω±0.1.

Notes:

• Goodwill amortization of ¥28.0 per share has been added back to earnings (to account for a non-cash expense and comparability with IFRS companies).
• Net assets as of the end of the quarter have been used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit five-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it does not forecast market prices or recommend any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through integrated analysis of XBRL earnings release data and PDF earnings presentation materials. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Asahi Kasei delivered a strong FY2027 Q1 earnings recovery, led by substantial Materials segment profit improvement and broad revenue growth. Revenue increased 11.9% year on year to ¥826.2bn. Operating income rose 51.5% to ¥81.3bn, outpacing sales growth and demonstrating favorable operating leverage. Ordinary income increased 70.8% to ¥85.3bn. Profit attributable to owners of the parent surged 172.7% to ¥53.8bn, equivalent to EPS of ¥39.73. Gross margin expanded 250bp year on year to 35.1% from 32.6%. Operating margin expanded 257bp to 9.8% from 7.3%. Net margin expanded 384bp to 6.5% from 2.7%, aided by the earnings recovery and a much smaller net impact from exceptional items than in the previous year. Segment performance was strongest in Materials, where operating profit rose 160.4% to ¥38.8bn and margin improved to 10.7%. Healthcare also grew strongly, with sales up 23.0% and segment profit up 31.4%. Housing sales grew 3.3%, but segment profit declined 9.7%, indicating margin pressure in that business. Cash conversion was the principal weak point: operating cash flow was only ¥14.3bn against ¥53.8bn of owner-attributable profit, or 0.27x. The shortfall principally reflects a ¥73.3bn inventory build, while investing cash flow also included ¥131.7bn for subsidiary acquisitions. The April acquisition of Aicuris expanded Healthcare assets and added provisional goodwill of ¥44.6bn, increasing the importance of integration execution and future intangible-asset returns. Management’s full-year forecast implies Q1 progress of 25.4% for revenue, 32.8% for operating income, and 33.6% for owner-attributable profit; the profit progress is ahead of the seasonal 25% reference point. The ¥44 full-year DPS forecast equates to a 36.8% dividend payout ratio based on forecast EPS of ¥119.65, providing a reasonable earnings-based dividend cushion. The outlook now depends on whether Materials margin recovery can persist, Healthcare acquisition benefits can be realized, and the elevated inventory and investment outflows can normalize into cash generation.

Profitability Analysis

Annualized DuPont ROE is 9.8%, decomposed into a 6.5% net profit margin, 0.741x asset turnover, and 2.03x financial leverage. The principal source of the year-on-year return improvement is margin expansion rather than an assumed change in balance-sheet leverage: operating margin increased 257bp to 9.8% and net margin increased 384bp to 6.5%. Gross margin improved 250bp to 35.1%, showing that the operating-income gain was supported first by improved gross profitability. SG&A rose 11.9% to ¥209.0bn, exactly in line with revenue growth, so it did not dilute the gross-margin recovery; operating leverage was therefore favorable. EBITDA was ¥124.4bn, or a 15.1% margin, while EBITDA before JGAAP goodwill amortization was ¥133.9bn. Goodwill amortization of ¥9.4bn represented 7.6% of EBITDA, a moderate JGAAP accounting drag that should be considered when comparing the group with IFRS-reporting peers. The five-factor framework shows a 0.622 tax burden and an interest burden of 1.063; pre-tax profit exceeded EBIT because non-operating income exceeded interest and other non-operating costs. The 35.1% effective tax rate is relatively high and limited conversion of pre-tax profit into net profit. Materials is the core business by segment operating-income contribution, generating ¥38.8bn of segment profit, ahead of Healthcare at ¥29.8bn and Housing at ¥20.2bn. Materials sales increased 13.8% to ¥360.2bn and its segment margin rose to 10.7% from 4.7%, making it the largest contributor to consolidated earnings improvement. Healthcare sales increased 23.0% to ¥190.8bn and operating profit increased 31.4% to ¥29.8bn, with margin improving 100bp to 15.6%. Housing sales were ¥267.6bn, up 3.3%, but segment profit declined to ¥20.2bn from ¥22.4bn, reducing margin by 107bp to 7.5%. The durability of the consolidated recovery therefore rests particularly on sustaining Materials spreads and restoring Housing profitability.

Growth Assessment

Growth was broad based, with each principal segment reporting higher sales. Healthcare produced the fastest sales growth at 23.0%, supported by the acquired Aicuris business and other expansion. The acquisition is strategically meaningful: Healthcare segment assets increased ¥160.3bn versus the prior fiscal year-end, and the transaction contributed provisional goodwill of ¥44.6bn. Materials sales growth of 13.8% was accompanied by a ¥23.9bn increase in segment operating profit, indicating a sharp recovery in segment economics rather than volume-only growth. Housing growth was more modest at 3.3%, and its declining profit means further sales growth alone would not guarantee earnings growth. Full-year company guidance calls for revenue of ¥3,254.0bn, up 5.8%, and operating income of ¥248.0bn, up 7.3%. Q1 revenue progress of 25.4% is close to the normal 25% seasonal benchmark. Operating-income progress of 32.8%, ordinary-income progress of 34.5%, and owner-attributable-profit progress of 33.6% are 7.8-9.5 percentage points ahead of the normal Q1 benchmark, indicating an earnings front-load relative to guidance. This degree of outperformance is constructive, but it also raises the requirement for the group to sustain current Materials profitability through the remaining quarters. The forecast has been revised, which signals management has updated its outlook during the period. Revenue sustainability should be assessed through Materials pricing and demand conditions, Healthcare post-acquisition sales and R&D productivity, and Housing margin recovery.

Financial Health

Liquidity is sound, with a current ratio of 200.8%, a quick ratio of 159.1%, and working capital of ¥991.2bn. Cash and deposits of ¥387.4bn covered short-term loans of ¥197.5bn by 1.96x. Current assets of ¥1,974.8bn substantially exceeded current liabilities of ¥983.6bn, indicating no immediate maturity-mismatch pressure. Interest-bearing debt was ¥779.8bn, equivalent to D/E of 1.03x and debt/capital of 26.2%; these measures are manageable and remain below the thresholds associated with aggressive capital structures. Interest coverage was robust at 21.19x on EBIT and 32.43x on EBITDA, so the present interest-servicing burden is low. However, Debt/EBITDA of 6.27x is elevated above the 4.0x quality-alert threshold. The root cause is acquisition- and investment-related funding combined with a Q1 EBITDA denominator, while financing cash flow was a ¥186.0bn inflow. The leverage profile is partly mitigated by strong liquidity, a 25.3% short-term-debt ratio, and high interest coverage, but it increases sensitivity to any reversal in Materials earnings or disappointment in acquired Healthcare assets. Short-term loans increased ¥97.6bn year on year, or 97.7%, and were a major component of the period’s ¥138.6bn net increase in short-term borrowings. Bonds payable increased ¥57.5bn year on year to ¥307.5bn. Total equity increased ¥31.1bn to ¥2,196.7bn, but total assets expanded more quickly by ¥318.0bn to ¥4,456.8bn, lowering the capital adequacy ratio to 47.5% from 50.5%. Defined-benefit liabilities of ¥108.8bn are an additional long-dated obligation to monitor. The ¥17.9bn share repurchase increased treasury stock to negative ¥28.0bn from negative ¥10.1bn, representing a deliberate but modest use of capital alongside acquisition funding.

Notable B/S Changes

Short-term loans: +¥97.6bn (+97.7%) to ¥197.5bn - a substantial increase in short-dated funding alongside acquisition and investment cash outflows; liquidity coverage remains adequate at 1.96x cash/short-term debt. Treasury stock: -¥17.9bn, expanding from -¥10.1bn to -¥28.0bn (-176.2%) - reflects Q1 share repurchases of ¥17.9bn and adds to cash demands during an acquisition-funded period. Goodwill: +¥40.6bn (+10.6%) to ¥424.4bn - principally associated with the Aicuris acquisition, for which ¥44.6bn of provisional goodwill was recognized; future return realization and impairment testing are key. Intangible assets: +¥179.2bn (+19.5%) to ¥1,097.1bn - a large absolute increase that raises intangible assets to 24.6% of total assets and increases dependence on successful commercialization and amortization management. Total assets: +¥318.0bn (+7.7%) to ¥4,456.8bn - expansion was driven by acquisition-related assets, inventories, and investment activity, while capital adequacy declined to 47.5% from 50.5%. Construction in progress: +¥25.7bn (+12.1%) to ¥238.5bn - equivalent to 24.0% of PPE, indicating a substantial capital-project pipeline and elevated construction execution risk.

Cash Flow Quality

Cash-flow quality is the key earnings-quality concern. Operating cash flow was ¥14.3bn, only 0.27x owner-attributable net income of ¥53.8bn, materially below the 0.8x warning threshold. Cash conversion, measured as OCF/EBITDA, was only 0.11x, well below the 0.7x alert threshold. The principal root cause was working-capital absorption, especially the ¥73.3bn increase in inventories. Inventory days were flagged at 148 days under one measure and 70 days under another measure; both alerts indicate inventory efficiency requires active management, with the 148-day measure materially above the 90-day warning level. The cash conversion cycle was 169 days, above the 120-day warning threshold, extending the time required to convert production and sales into cash. This is particularly relevant for a diversified manufacturer because excess inventories can expose Materials businesses to price corrections, demand volatility, and obsolescence risk. Trade receivables changed only modestly, while trade payables increased ¥19.3bn, so supplier financing partly offset but did not neutralize inventory-related cash absorption. Accruals ratio was nevertheless low at 0.9%, below the 5% benchmark, which is supportive of balance-sheet accrual quality and indicates the weak OCF outcome is more visibly tied to working capital than to unusually high accounting accruals. Capital expenditure was ¥55.7bn and exceeded depreciation and amortization of ¥43.1bn, producing a CapEx/depreciation ratio of 1.29x and signaling expansionary or modernization-oriented investment. Construction in progress was ¥238.5bn, or 24.0% of PPE, exceeding the 20% quality-alert threshold. The root cause of the high CIP ratio is a large investment pipeline; its impact is execution risk, because delayed commissioning would defer returns while cash has already been committed. Free cash flow was negative ¥181.3bn, reflecting operating cash flow, capital expenditure, and the sizeable acquisition-related investing outflow. The ¥131.7bn subsidiary-acquisition payment equaled 15.9% of Q1 revenue, above the 10% M&A-intensity threshold, and was financed in significant part through borrowing. Consequently, a recovery in operating cash flow and inventory discipline are essential before considering current FCF generation as self-funding.

Dividend Sustainability

The full-year dividend forecast is ¥44 per share, unchanged in revision status, compared with forecast EPS of ¥119.65. The implied dividend-only payout ratio is 36.8%, below the 60% sustainability benchmark and therefore well covered by forecast accounting earnings. Cash dividends paid in Q1 were ¥29.9bn, while share repurchases were ¥17.9bn. Including these Q1 buybacks, cash shareholder returns were ¥47.8bn, which exceeded Q1 operating cash flow of ¥14.3bn. Free cash flow was negative ¥181.3bn because of capital expenditure and the Aicuris acquisition, so cash coverage of distributions was not achieved in the quarter. This does not by itself undermine the ordinary dividend because the balance sheet has substantial liquidity and the acquisition is non-recurring in nature, but it makes sustained working-capital improvement important. The current payout policy appears earnings-sustainable, whereas the pace of buybacks should be evaluated against post-acquisition deleveraging and cash conversion. The relevant capital-allocation measure when dividends and buybacks are both considered is total return ratio, rather than payout ratio; a full-year total return ratio cannot be inferred from the Q1 buyback alone.

Risk Assessment

Business risks include Materials-cycle risk: the segment’s ¥38.8bn operating profit and 10.7% margin drove the recovery, leaving consolidated earnings exposed to changes in chemical/materials demand, selling prices, feedstock costs, and competitive supply., Healthcare acquisition and integration risk: Aicuris added ¥44.6bn of provisional goodwill and increased Healthcare segment assets by ¥160.3bn; realizing strategic returns depends on integration, product development, commercialization, and final purchase-price allocation., Inventory and supply-chain risk: inventory-related cash absorption of ¥73.3bn, alerts for 148-day and 70-day DIO measures, and a 169-day cash conversion cycle increase exposure to demand corrections, carrying costs, and potential inventory valuation pressure., Housing margin risk: segment profit declined 9.7% despite 3.3% sales growth, leaving the segment exposed to construction input costs, labor availability, pricing discipline, and residential demand conditions., Manufacturing execution risk: construction in progress of ¥238.5bn, equal to 24.0% of PPE, creates risk of project delay, cost overruns, or returns below the cost of capital..

Financial risks include High leverage alert: Debt/EBITDA of 6.27x exceeds the 4.0x alert threshold. Although interest coverage is strong and D/E is only 1.03x, elevated debt relative to EBITDA reduces flexibility if operating conditions weaken., Acquisition funding risk: ¥131.7bn of subsidiary-acquisition spending was accompanied by ¥186.0bn of financing inflows and a ¥97.6bn year-on-year increase in short-term loans., Cash-conversion risk: OCF/owner-attributable profit of 0.27x and OCF/EBITDA of 0.11x indicate that reported profitability has not yet translated into cash generation., Intangible-asset valuation risk: goodwill was ¥424.4bn, or 19.3% of equity, while intangible assets represented 24.6% of assets. These levels are not in the warning range for goodwill concentration, but they heighten the importance of acquired-asset performance and impairment testing., Foreign-exchange sensitivity: Q1 included ¥5.0bn of FX gains in non-operating income, and the group’s overseas operations and acquisition activity can create translation and transaction exposure..

Key concerns include Highest priority is normalization of inventory and cash conversion, because current operating cash flow does not support the level of investment and shareholder distributions without external funding., Second priority is maintaining Materials profitability; the segment accounted for the largest operating-profit contribution and the majority of the year-on-year segment-profit increase., Third priority is disciplined post-acquisition capital allocation, including debt management, finalization of Aicuris purchase accounting, and evidence that the acquired assets can earn adequate cash returns., The quality alerts are partly mitigated by a 200.8% current ratio, 1.96x cash/short-term-debt coverage, and EBITDA interest coverage of 32.43x, but these do not remove the need for cash-flow improvement..

Investment Implications

Key takeaways include Revenue growth of 11.9% and operating-income growth of 51.5% confirm a significant earnings rebound, with operating margin reaching 9.8%., Materials is the core earnings engine in Q1, with ¥38.8bn operating profit and a 603bp segment-margin expansion., Healthcare combines strong organic/portfolio growth with material M&A exposure following the Aicuris acquisition., The Q1 profit run rate is ahead of full-year guidance, but cash generation materially lags earnings because of inventory growth and acquisition spending., Balance-sheet liquidity and interest coverage are strong, yet Debt/EBITDA of 6.27x means deleveraging and operating cash-flow conversion remain important..

Metrics to watch include Materials segment sales, operating margin, and sensitivity to selling prices and input costs, Housing segment margin recovery, Operating cash flow relative to owner-attributable profit and EBITDA, Inventory balance, inventory days, and cash conversion cycle, Net debt, Debt/EBITDA, and short-term borrowing movements, Aicuris integration milestones, Healthcare profitability, goodwill, and intangible-asset amortization or impairment, Construction-in-progress conversion into productive operating assets, Progress against full-year operating-income guidance and maintenance of the ¥44 DPS forecast.

Regarding relative positioning, The company presents a mixed profile of improved industrial profitability, resilient liquidity, and a moderate earnings-based dividend commitment, offset by weaker-than-desired cash conversion and acquisition-related leverage. JGAAP goodwill amortization depresses reported operating and net earnings relative to an IFRS treatment, although the ¥9.4bn charge is moderate at 7.6% of EBITDA. Goodwill/Equity of 19.3% and goodwill/EBITDA of 3.41x remain within healthy M&A benchmarks, but the acquisition’s cash funding and associated intangible concentration make return realization more important than the headline accounting metrics alone.